Medicare Enrolled
Dr. Mark Jennings, MD
Student in an Organized Health Care Education/Training Program · Allen, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jennings from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jennings? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jennings
Dr. Mark Jennings is a student in an organized health care education/training program in Allen, TX, with 16 years in practice. Based on federal Medicare data, Dr. Jennings performed 137,660 Medicare services across 5,621 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jennings received a total of $3,539 from 46 pharmaceutical and/or device companies across 190 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jennings is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 0% volume in TX$ $3,539 industry payments
Medicare Practice Summary
Medicare Utilization ↗137,660
Medicare services
Top 0% in TX for student in an organized health care education/training program
5,621
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,604 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 15,820 | $24 | $64 |
| Contrast dye for imaging (iodine-based) | 15,025 | $0 | $1 |
| Iron infusion (Injectafer) | 15,000 | $1 | $3 |
| Paclitaxel chemotherapy injection | 12,963 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 11,800 | $43 | $114 |
| Injection, granisetron, extended-release, 0.1 mg | 9,600 | $5 | $12 |
| Anti-nausea injection (aprepitant) | 8,060 | $1 | $5 |
| Daratumumab injection (Darzalex) | 7,380 | $38 | $110 |
| Oxaliplatin chemotherapy injection | 6,400 | $0 | $4 |
| Dexamethasone injection (steroid) | 3,932 | $0 | $1 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,168 | $26 | $88 |
| Injection, docetaxel, 1 mg | 2,200 | $1 | $9 |
| Epoetin alfa injection (Retacrit) for anemia | 1,760 | $6 | $28 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,670 | $26 | $158 |
| Injection, bortezomib, 0.1 mg | 1,540 | $4 | $116 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 1,390 | $53 | $181 |
| Complete blood count (CBC) with differential | 1,268 | $8 | $26 |
| Comprehensive metabolic blood panel | 1,207 | $10 | $36 |
| Immune globulin infusion (Gammagard) | 1,090 | $35 | $100 |
| Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | 960 | $23 | $205 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 950 | $24 | $185 |
| Lactate dehydrogenase (enzyme) level | 929 | $6 | $21 |
| Magnesium level test | 866 | $7 | $23 |
| Phosphate level test | 866 | $5 | $16 |
| Uric acid level test | 864 | $4 | $15 |
| Blood draw (venipuncture) | 804 | $8 | $13 |
| Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 731 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 650 | $20 | $69 |
| Office visit, established patient (30-39 min) | 625 | $87 | $253 |
| Anti-nausea injection (Aloxi/palonosetron) | 620 | $1 | $56 |
| Injection, leucovorin calcium, per 50 mg | 537 | $3 | $15 |
| Administration of chemotherapy into vein, 1 hour or less | 485 | $90 | $300 |
| Injection, fulvestrant, 25 mg | 410 | $9 | $235 |
| Injection, carboplatin, 50 mg | 401 | $2 | $43 |
| Injection, fluorouracil, 500 mg | 374 | $2 | $6 |
| Flow cytometry, additional marker | 361 | $17 | $101 |
| Anti-nausea injection (ondansetron/Zofran) | 304 | $0 | $2 |
| Drug injection, under skin or into muscle | 280 | $10 | $57 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 224 | $3 | $48 |
| Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 216 | $103 | $843 |
| Cyclophosphamide, 100 mg | 188 | $15 | $105 |
| Administration of chemotherapy into vein, each additional hour | 165 | $20 | $65 |
| Ferritin level test (iron stores) | 162 | $13 | $46 |
| Iron level test | 162 | $6 | $19 |
| Iron binding capacity test | 162 | $9 | $30 |
| Ct scan of chest with contrast | 149 | $44 | $500 |
| Administration of additional new drug or substance into vein, 1 hour or less | 145 | $45 | $140 |
| Injection, diphenhydramine hcl, up to 50 mg | 139 | $1 | $2 |
| Injection, gadopiclenol, 1 ml | 137 | $9 | $11 |
| Unclassified drugs | 135 | $566 | $1,803 |
| CT scan of abdomen and pelvis with contrast | 133 | $150 | $603 |
| Thyroid stimulating hormone (TSH) test | 132 | $16 | $57 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 127 | $43 | $155 |
| Injection, doxorubicin hydrochloride, 10 mg | 127 | $2 | $7 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 121 | $50 | $166 |
| Injection, zoledronic acid, 1 mg | 120 | $7 | $126 |
| Office visit, established patient, complex (40-54 min) | 114 | $127 | $342 |
| Reticulated (young) platelet measurement | 103 | $35 | $91 |
| Injection of additional new drug or substance into vein | 93 | $11 | $50 |
| Irrigation of implanted venous access drug delivery device | 88 | $17 | $55 |
| Office visit, established patient (20-29 min) | 86 | $56 | $173 |
| Blood creatinine level | 85 | $5 | $17 |
| Carcinoembryonic antigen (cea) protein level | 83 | $19 | $65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 68 | $24 | $73 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 67 | $125 | $450 |
| Immunoglobulin level test | 60 | $9 | $32 |
| Infusion, normal saline solution , 1000 cc | 58 | $2 | $17 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 54 | $1,033 | $4,084 |
| Infusion into a vein for hydration, each additional hour | 54 | $8 | $35 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 51 | $137 | $550 |
| Injection, magnesium sulfate, per 500 mg | 50 | $1 | $4 |
| Administration of additional new drug or substance into vein using push technique | 46 | $39 | $139 |
| New patient office visit (45-59 min) | 43 | $118 | $389 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 41 | $14 | $45 |
| CT scan of chest, without contrast | 40 | $42 | $409 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $118 | $1,000 |
| Prothrombin time test (blood clotting) | 29 | $4 | $13 |
| Mri scan of brain before and after contrast | 28 | $141 | $1,456 |
| Urine microalbumin (protein) analysis | 24 | $6 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 24 | $14 | $47 |
| Red blood count, automated test | 21 | $4 | $14 |
| Initial hospital admission, high complexity | 20 | $127 | $489 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 19 | $1 | $12 |
| Flow cytometry technique for dna or cell analysis, first marker | 18 | $49 | $166 |
| New patient office visit, complex (60-74 min) | 17 | $163 | $490 |
| Initial hospital admission, moderate complexity | 17 | $92 | $331 |
| Hospital follow-up visit, high complexity | 17 | $90 | $251 |
| Ct scan of abdomen and pelvis without contrast | 16 | $71 | $288 |
| Mri scan of abdomen before and after contrast | 14 | $177 | $1,548 |
| CT guidance for radiation therapy | 14 | $87 | $314 |
| Nuclear medicine study whole body with ct scan | 14 | $1,032 | $4,180 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 13 | $253 | $1,023 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.4% high complexity
80.4% medium
7.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,539
Total received (2018-2024)
Avg $506/year across 7 years
Top 10% in TX for student in an organized health care education/training program
46
Companies
190
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,311 (65.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,228 (34.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$738
2023$818
2022$555
2021$242
2020$285
2019$610
2018$290
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$1,026
Novartis Pharmaceuticals Corporation
$287
Merck Sharp & Dohme Corporation
$180
Alexion Pharmaceuticals, Inc.
$163
E.R. Squibb & Sons, L.L.C.
$134
INTUITIVE SURGICAL, INC.
$130
Pharmacyclics LLC, an AbbVie Company
$105
Genentech USA, Inc.
$103
Veran Medical Technologies, Inc.
$84
Ipsen Biopharmaceuticals, Inc
$81
AstraZeneca Pharmaceuticals LP
$77
GENZYME CORPORATION
$72
GlaxoSmithKline, LLC.
$68
Astellas Pharma US Inc
$61
Taiho Oncology, Inc.
$60
Seagen Inc.
$56
Regeneron Healthcare Solutions, Inc.
$55
Bayer Healthcare Pharmaceuticals Inc.
$52
Teva Pharmaceuticals USA, Inc.
$50
Takeda Pharmaceuticals U.S.A., Inc.
$50
Gilead Sciences, Inc.
$48
Celgene Corporation
$42
Merck Sharp & Dohme LLC
$36
Janssen Pharmaceuticals, Inc
$35
Daiichi Sankyo Inc.
$35
Karyopharm Therapeutics Inc.
$35
Genmab U.S., Inc.
$33
RECORDATI_RARE_DISEASES_INC.
$32
Bayer HealthCare Pharmaceuticals Inc.
$29
ADC Therapeutics America, Inc.
$28
Lilly USA, LLC
$27
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
AbbVie, Inc.
$25
PharmaEssentia USA Corporation
$23
ABBVIE INC.
$22
Pharmacyclics LLC, An AbbVie Company
$21
BeiGene USA, Inc.
$18
Amgen Inc.
$17
SANOFI-AVENTIS U.S. LLC
$17
Incyte Corporation
$16
Janssen Biotech, Inc.
$16
Blue Earth Diagnostics Limited
$16
Acrotech Biopharma LLC
$14
Kyowa Kirin, Inc.
$12
Puma Biotechnology, Inc.
$12
EISAI INC.
$11
Top 3 companies account for 42.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · Axumin · BELEODAQ · BENDEKA · BESREMI · BRAFTOVI · BRUKINSA · Da Vinci Surgical System · ELITEK · EPKINLY · Enhertu · Epkinly · FARESTON · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LENVIMA · LIBTAYO · LYNPARZA · Lenvima · Lonsurf · MVASI · NERLYNX · NINLARO · Nubeqa · OJJAARA · OPDIVO · Onivyde · PADCEV · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · REBLOZYL · RYDAPT · SCEMBLIX · SUTENT · SYLVANT · Soliris · Spin · Stivarga · TECENTRIQ · TUKYSA · Trodelvy · ULTOMIRIS · VENCLEXTA · Venclexta · Vyloy · XARELTO · XOSPATA · XPOVIO · XTANDI · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (65%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for student in an organized health care education/training program in TX.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Student in an Organized Health Care Education/Training Programs within 10 mi
5,378
Per 100K population
481.6
County median income
$117,588
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL ALLEN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Jennings is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), and high industry engagement (low-engagement, top 10%), with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Jennings experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Jennings performed 15,820 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jennings receive payments from pharmaceutical companies?
Yes. Dr. Jennings received a total of $3,539 from 46 companies across 190 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jennings's costs compare to other student in an organized health care education/training programs in Allen?
Dr. Jennings's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jennings) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Student in an Organized Health Care Education/Training Programs in Allen
Browse student in an organized health care education/training programs in Allen ranked by procedure volume and transparency data.
Highest volume
Top Student in an Organized Health Care Education/Training Programs in TX
Student in an Organized Health Care Education/Training Programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student in an Organized Health Care Education/Training Programs in TX
Which TX student in an organized health care education/training programs receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology